Search

Your search keyword '"Advani, Ranjana"' showing total 2,053 results

Search Constraints

Start Over You searched for: Author "Advani, Ranjana" Remove constraint Author: "Advani, Ranjana"
2,053 results on '"Advani, Ranjana"'

Search Results

1. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

4. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma

5. Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation

7. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

8. DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set

9. Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium

11. Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era

12. The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network

16. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

17. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients

18. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

19. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV

20. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

21. Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience

23. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

25. Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma

27. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

28. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

29. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.

30. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

31. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma

33. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center

36. Current Frontline Treatment of Diffuse Large B-Cell Lymphoma

37. Emerging immunotherapies in the Hodgkin lymphoma armamentarium.

39. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

40. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma

41. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

42. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG

43. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

44. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

45. Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era

46. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

47. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial

48. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

50. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

Catalog

Books, media, physical & digital resources